Wyman Thomas Mcguirt, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5 First Village Drive, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0244 |
Dr. Waldemar L Riefkohl, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5 First Village Dr, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0244 |
Dr. Matthew Ryan Grafenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5 Firstvillage Drive, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0244 |
Jefferson Kirby Kilpatrick, M.D. Otolaryngology - Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5 First Village Drive, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0244 |
Carl W Berk, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5 Firstvillage Drive, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0874 |
Stanley Cullen Cox Iii, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 5 Firstvillage Drive, Pinehurst, NC 28374 Phone: 910-295-6831 Fax: 910-295-0244 |
News Archive
A world-first study led by Monash University has demonstrated significant benefits to a premature baby's heart and brain function when held by the parent in skin-to-skin contact.
A major new report by think tank, The Stockholm Network, shows policy makers are not doing enough to tackle rising cholesterol levels.
Wavering moderates, including Sens. Mary Landrieu, D-La., Blanche Lincoln, D-Ark., Ben Nelson, D-Neb., and Joe Lieberman, I-Conn., control the key votes needed to bring the health overhaul bill to the Senate floor, so securing their agreement to go forward has become a priority for the Democratic leadership.
Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.
"With rising health care costs and 30 percent of privately insured adults enrolled in high-deductible health care plans, calls for greater health care price transparency are increasing. In response, health plans, consumer groups, and state governments are increasingly reporting health care prices.
› Verified 1 days ago